Showing results (471-480 of 484) with videos related to
Sort By:
Pageof 49
European Urology Focus|July 30, 2017
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient CohortJennifer Cullen, Denise Young, Yongmei Chen, et al.Journal of Translational Medicine|January 9, 2020
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancerMichael A Kiebish, Jennifer Cullen, Prachi Mishra, et al.The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.The Journal of Urology|May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancerS A Loening, S Beckley, M F Brady, et al.Journal of Surgical Oncology|June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostateR P Gibbons, S Beckley, M F Brady, et al.Journal of Translational Medicine|April 19, 2015
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methodsJintang He, Athena A Schepmoes, Tujin Shi, et al.Cancer|September 5, 2019
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancerCelestia S Higano, Andrew J Armstrong, A Oliver Sartor, et al.Prostate Cancer and Prostatic Diseases|March 1, 2020
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registryOliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 23, 2023
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19B Joseph Elmunzer, Olafur S Palsson, Nauzer Forbes, et al.BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.Pageof 49